Targeting DNA repair pathways for ADC-resistant HER2+ breast cancer

Dr. Hong's Biotechnology Lecture 04: Cancers and Antibody Drug ConjugateПодробнее

Emerging strategies to overcome resistance to HER2 ADCs in breast cancerПодробнее

Overcoming resistance to HER2-directed ADCs in HER2+ breast cancerПодробнее

TROP2-Targeting ADCs as New Tools in the TNBC and HR+/HER2- Breast Cancer Treatment ArsenalПодробнее

MS1 Targeting DNA damage response and HRD in breast cancer Timothy A. YapПодробнее

EMBRACA & OlympiAD: targeting DNA repairПодробнее

Resistance to ADCs in breast cancer and novel combination strategiesПодробнее

Emerging Antibody-Drug Conjugates in Breast Cancer: An Expert Analysis of Promising TherapiesПодробнее

Novel Therapeutics for Breast Cancer: HER2+ and Triple Negative Disease; New Pathways, TargetsПодробнее

TROP2: A Promising Breast Cancer Drug TargetПодробнее

ADCs for the treatment of HER2-low breast cancerПодробнее

Promising targets in ADCs for breast cancerПодробнее

The evolving role of antibody-drug conjugates in the treatment of urothelial carcinomaПодробнее

Advances in novel ADCs for HER2-expressing breast cancerПодробнее

Treating Breast Cancer with EGFR ADC - Antibody Drug ConjugatesПодробнее

Education Session Genomics for Clinical Research and Cancer CareПодробнее

Antibody drug conjugates in lung cancerПодробнее

Antibody Drug Conjugates: The end of chemotherapy | 2023 West Oncology ConferenceПодробнее

Are You Prepared for the New Wave of ADCs in NSCLC? Targeting HER2, HER3, TROP2, and OthersПодробнее